Raymond James raises Relay Therapeutics price target on trial data By Investing.com

Raymond James raised Relay Therapeutics’ price target to $23 from $19 and kept a Strong Buy rating after the company disclosed encouraging proof-of-concept data for zovegalisib combinations in HR+/HER2- PIK3CAmut metastatic breast cancer. The firm said efficacy in dose escalation matched expectations and safety looked favorable, supporting a planned frontline Phase 3 program in early 2027. The stock trades at $14.98 after a 373% one-year gain, though it fell 7.7% over the past week.

Analysis

The market is starting to treat RLAY less like a binary early-stage biotech and more like an asset with a visible franchise path in a large tumor niche. That matters because once a program graduates from “interesting data” to “frontline pivotal design,” the stock tends to re-rate on probability-weighted peak sales rather than near-term readout quality; the catalyst window shifts from days to quarters. The incremental signal here is not just efficacy — it is that safety appears compatible with the CDK4/6 backbone, which materially lowers the odds of a dead-end combination story and improves the odds of commercial sequencing.

The second-order winner may be the broader class of oral oncology combination enablers. If zovegalisib can be positioned as a better-tolerated PI3Kα backbone, that pressures competing assets by forcing them to prove not only activity but convenience, tolerability, and line-of-therapy flexibility. The competitive implication for NVS is less about this one asset and more about whether strategic M&A premiums in oncology become a live benchmark for smaller targeted-therapy names; that tends to compress the discount rate across the space and make platform biotechs harder to short.

The main risk is that the current enthusiasm is pulling forward a 2027 development story into a 2025-2026 valuation today. The stock has already absorbed a large amount of good news, so the next 10-20% move likely depends on dose-expansion durability, not headline response rates. Any signal that frontline tolerability erodes with longer exposure, or that the study design becomes more cumbersome than expected, would likely hit the shares faster than a modest efficacy miss because investors are paying for clean execution.

The contrarian view is that consensus may be underestimating how much of the upside is now already reflected in analyst target resets. A strong readout can still lead to a stalled stock if the market decides the path to commercialization is too far out and too competitive versus better-capitalized oncology franchises. That creates an interesting asymmetry: good data supports the long-term story, but the near-term trade may be better expressed as a volatility event than a pure directional bet.

Key Decisions for Investors

• Add RLAY on pullbacks into the next 3-5 trading sessions; use a 6-12 month horizon and size for binary clinical execution risk, with upside tied to continued de-risking of frontline pivotal entry.
• Buy RLAY Jan-2026 or Jan-2027 calls rather than common stock if available liquidity supports it; the setup favors convexity because the valuation inflection is being driven by future development milestones, not current revenue.
• Pair long RLAY / short a basket of lower-quality oncology beta names over the next 1-3 months; if the market keeps rewarding clinically de-risked combo assets, the higher-quality balance sheet and clearer path should outperform weaker peers.
• Avoid chasing NVS on the read-through; treat any sympathy bid as temporary and look for an entry only if M&A premium expectations broaden across the space, which would be a better setup for a relative-value long than outright momentum.
• If RLAY rallies another 15-20% without new data, consider trimming into strength and resetting on the next catalyst, because the market is likely to become more sensitive to duration and execution risk than to additional analyst target hikes.